Pre-treatment role of inosine triphosphate pyrophosphatase polymorphism for predicting anemia in Egyptian hepatitis C virus patients

Table 1 Basal demographic and biochemistry criteria of all patients (mean ± SD)

Criteria	Total
Number	102
Age (yr)	32.5 ± 7.3
Sex (male/female)	90/12
BMI	25.6 ± 2.7
Baseline Hb (g/dL)	14.07 ± 1.1
plt (× 103/μL)	238.5 ± 62.7
WBCs (× 103/μL)	6.3 ± 1.4
ALT > ULN, n (%)	78 (76.5)
Creatinine level (mg/dL)	0.91 ± 0.44
Baseline HCV RNA (log IU/mL)	5.4 ± 0.7
Metavir fibrosis stage, n (%)
F1	69 (67.7)
F2	30 (29.4)
F3	3 (2.9)
Grade of inflammation, n (%)
A1	64 (62.7)
A2	33 (29.4)
A3	5 (5.4)
PEG IFN, n (%) (dose)
α2a	72 (70.6) (180 μg/wk)
α2b	30 (29.4) (1.5 μg/kg per week)
Ribavirin dose (mg/kg per day)	12.5 (10-15)
HCV genotype (G), n (%)	G4, 62 (60.8); G1, 40 (39.2)

Hb: Hemoglobin; BMI: Body mass index; plt: Platelet; WBCs: White blood cells; ALT: Alanine aminotransferase; ULN: Upper limit of normal of ALT = 12 IU/L; HCV: Hepatitis C virus; PEG-IFN: Pegylated interferon.